A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Myelodysplastic Syndromes

In brief

This Phase II was a multicenter, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to hypomethylating agents (azacitidine or decitabine) in adult subjects with IPSS-R intermediate, high or very high risk myelodysplastic syndrome (MDS) not eligible for Hematopoietic Stem Cell Transplant (HSCT) or intensive chemotherapy.

Key facts

Study ID

NCT03946670

Run by

Novartis Pharmaceuticals

People needed

127

Starts

2019-06-04

Expected to finish

2024-07-15

Last updated by the study team

2026-01-13

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent must be obtained prior to participation in the study.
• Age ≥ 18 years at the date of signing the informed consent form (ICF)-. Morphologically confirmed diagnosis of a myelodysplastic syndrome (MDS) based on 2016 WHO classification (Arber et al 2016) by investigator assessment with one of the following Prognostic Risk Categories, based on the International Prognostic Scoring System (IPSS-R):
• Very high
• High
• Intermediate with at least ≥ 5% bone marrow blast
• Not eligible at the time of screening, for intensive chemotherapy according to the investigator, based on local standard medical practice and institutional guidelines for treatment decisions
• Not eligible at the time of screening, for hematopoietic stem-cell transplantation (HSCT) according to the investigator, based on local standard medical practice and institutional guidelines for treatment decisions.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

You may not qualify if…

• Prior exposure to TIM-3 directed therapy at any time. Prior therapy with immune check point inhibitors (e.g. anti-CTLA4, anti-PD-1, anti-PD-L1, or anti-PD-L2), cancer vaccines are allowed except if the drug was administered within 4 months prior to randomization.
• Previous first-line treatment for higher risk MDS with chemotherapy or any other antineoplastic agents including lenalidomide and hypomethylating agent (HMAs) such as decitabine or azacitidine.
• History of severe hypersensitivity reactions to any ingredient of the study treatment (azacitidine, decitabine or MGB453) or their excipients, or to monoclonal antibodies (mAbs).
• Currently using or used within 14 days prior to randomization of systemic, steroid therapy (> 10 mg/day prednisone or equivalent) or any immunosuppressive therapy. Topical, inhaled, nasal, ophthalmic steroids are allowed. Replacement therapy, steroids given in the context of a transfusion are allowed and not considered a form of systemic treatment.
• Investigational treatment for MDS received within 4 weeks prior to randomization. In case of a checkpoint inhibitor: 4 months minimum prior to randomization interval is necessary to allow enrollment.
• Active autoimmune disease requiring systemic therapy (e.g.corticosteroids).
• Live vaccine administered within 30 Days prior to randomization.

Where it is running

• City Of Hope National Med Center — Duarte, California, United States
• City of Hope National Medical Center Medical Oncology & Therapeutic — Duarte, California, United States
• Yale University School Of Medicine — New Haven, Connecticut, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• The Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
• Ohio State Comprehensive Cancer Center James Cancer Hospital — Columbus, Ohio, United States
• Mary Crowley Cancer Research — Dallas, Texas, United States
• Novartis Investigative Site — Vienna, Austria
• Novartis Investigative Site — Brasschaat, Belgium
• Novartis Investigative Site — Leuven, Belgium
• Novartis Investigative Site — Toronto, Ontario, Canada
• Novartis Investigative Site — Québec, Quebec, Canada
• Novartis Investigative Site — Brno, Czechia
• Novartis Investigative Site — Prague, Czechia
• Novartis Investigative Site — Toulouse, France
• Novartis Investigative Site — Leipzig, Saxony, Germany
• Novartis Investigative Site — Berlin, Germany
• Novartis Investigative Site — Alexandroupoli, Greece
• Novartis Investigative Site — Larissa, Greece
• Novartis Investigative Site — Pátrai, Greece
• Novartis Investigative Site — Hong Kong, Hong Kong
• Novartis Investigative Site — Debrecen, Hajdu Bihar Megye, Hungary
• Novartis Investigative Site — Nyíregyháza, Hungary
• Novartis Investigative Site — Florence, FI, Italy
• Novartis Investigative Site — Milan, MI, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.